Researchers Explore Baricitinib as a New Treatment for Sjögren’s Disease

A promising development in autoimmune disease research may lead to more effective treatment options for people living with Sjögren’s disease, a chronic condition known for causing dry eyes, dry mouth, fatigue, and joint pain. A new study suggests that baricitinib, a medication currently used to manage rheumatoid arthritis, could also alleviate the debilitating symptoms of Sjögren’s.

The findings, published in Science Translational Medicine, highlight the drug’s potential to reduce inflammation and restore saliva production in lab models. While human trials are still needed, the research opens the door to a possible therapeutic breakthrough for millions.

---

What Is Sjögren’s Disease?

Sjögren’s disease is an autoimmune condition in which the immune system mistakenly attacks the body’s moisture-producing glands. It primarily affects the salivary and tear glands, resulting in persistent dryness of the mouth and eyes. Beyond dryness, patients often suffer from:

• Fatigue
• Muscle or joint pain
• Rashes
• Lung inflammation

It is the second most common autoimmune rheumatic disease in the United States, affecting approximately 4 million people, according to the Sjögren’s Foundation.

---

Why Dry Mouth Matters for Oral Health

Dry mouth isn’t just uncomfortable—it can have serious consequences for oral health. Saliva plays a crucial role in neutralizing acids, washing away food debris, and protecting teeth and gums. When saliva production is impaired:

• Speech and eating become more difficult
• Cavity risk increases
• Gum health may decline
• Overall oral and systemic health is compromised

That’s why effective management of Sjögren’s symptoms is so vital—not only for comfort but also for long-term oral health outcomes.

---

The Science Behind the Breakthrough

The research team at NYU Grossman School of Medicine and NYU College of Dentistry focused on the underlying immune dysfunction driving Sjögren’s. In both mice and human samples, they found that interferon gamma, an inflammatory molecule, disrupts saliva production when regulatory T cells fail to keep immune responses in check.

To test a possible solution, scientists administered baricitinib, a JAK inhibitor already approved for rheumatoid arthritis. JAK inhibitors are designed to suppress overactive immune signaling, including that triggered by interferon.

Key Findings:

• Mice treated with baricitinib showed increased saliva production
• Inflammation in the salivary glands was significantly reduced
• Genetic parallels between human patients and lab models reinforced the relevance of the findings

---

What Comes Next?

While the early results are promising, clinical trials in humans will be necessary to determine the safety and effectiveness of baricitinib for treating Sjögren’s disease. If successful, it could represent a major advancement for a condition with limited treatment options.

Dr. Stefan Feske, the study’s senior author, expressed optimism:

“Using baricitinib has great promise in the treatment of Sjögren’s disease going forward.”

---

Why It Matters

For patients living with chronic dryness, fatigue, and inflammation, this research could pave the way for targeted therapies that not only manage symptoms but also improve quality of life. It may also help reduce the long-term dental complications associated with dry mouth.

---

Conclusion

Though more research is needed, baricitinib offers a hopeful new path for treating Sjögren’s disease. As clinical trials progress, patients and providers alike are watching closely for developments that could bring relief to the millions affected by this complex autoimmune disorder.